Long-Term Outcomes of Coronary and Carotid Artery Disease Revascularization in the FRIENDS Study

Table 3

Unadjusted comparison of primary and secondary endpoints for the 3 groups.

	Surgical	Endovascular	Hybrid	Surgical vs. Endovascular	Surgical vs. Hybrid	Endovascular vs. Hybrid	P value
	Event rates, n (%)			HR (95% CI)
Any death	43 (11.3%)	72 (14.5%)	21 (16.9%)	0.8 (0.6-1.2)	0.6 (0.3-1.1)	0.7 (0.4-1.3)	.173
Non CV death	17 (4.5%)	34 (6.9%)	11 (8.9%)	0.7 (0.4-1.2)	0.4 (0.2-1.1)	0.6 (0.3-1.4)	.102
CV death	26 (6.8%)	38 (7.7%)	10 (8.2%)	0.9 (0.6-1.5)	0.8 (0.4-1.7)	0.9 (0.4-1.8)	.829
MI	12 (3.3%)	23 (4.7%)	11 (9.1%)	0.7 (0.4-1.4)	0.3 (0.1-0.9)	0.5 (0.2-1.2)	.019
Stroke	6 (1.6%)	13 (2.6%)	3 (2.5%)	0.7 (0.3-1.7)	0.6 (0.1-2.5)	0.8 (0.3-3.4)	.669
CKD/haemodialysis	19 (5.2%)	35 (7.1%)	15 (12.5%)	0.7 (0.4-1.7)	0.7 (0.4-1.7)	0.6 (0.3-1.2)	.020
MACCE	37 (10.1%)	64 (13.0%)	16 (13.2%)	0.9 (0.6-1.4)	0.6 (0.3-1.2)	0.7 (0.4-1.3)	.257
All events	58 (15.9%)	117 (23.8%)	32 (26.5%)	0.8 (0.6-1.1)	0.5 (0.3-0.8)	0.7 (0.4-1.1)	.006

= surgical versus hybrid. CKD=chronic kidney disease; CV=Cardiovascular; MACCE = Major Adverse Cardiac and Cerebrovascular Events; MI=Myocardial Infarction.